Shares of Protagonist Therapeutics PTGX have gained nearly 7% over the past week. The upside came after the company announced ...

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that met ...

Johnson & Johnson’s Icotyde receives US FDA approval for first-line systemic treatment of plaque psoriasis with a targeted oral peptide: Spring House, Pennsylvania Friday, March ...

T he recent reimbursement of Bimzelx (bimekizumab) in Ireland represents an important step forward in access to treatment for people living with immune-mediated diseases, includin ...

Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psorias ...

Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pill ICOTYDE ...

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for moderate-to-severe plaque psoriasis in adults and pediatric ...

Around-the-clock performances presented using cutting-edge holograms intended to show hundreds of thousands of visitors ...

The multi-year partnership will help enterprises build future-ready workforces by combining AI-powered learning, assessment, and cloud-led transformation at scale.LONDON and MUMBAI, March 18, ...

Pearson (FTSE: PSON.L), the world's lifelong learning company, and Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS), a global leader in IT services and consulting, have announced a multi-year ...

When you’ve been around for over 30 years like Supreme has, you get the chance to work on plenty of collaborations. When most people think of Supreme and luxury, their mind likely goes to the massive ...